- Trial phase
- Phase 1
- Time to market
- Still in Phase 1 dose escalation; assuming successful Phase 1/2 and pivotal trials, potential approval would be several years away, likely 2029 or later.
- Why 6/10
- The next hard, dated catalyst is the next clinical update and initiation of expansion cohorts for the Phase 1 STRIVE-01 study, planned for the first half of 2027. This is roughly 6-12 months out and STRO-004 is Sutro's lead wholly-owned asset, but the company also has STRO-006 and other pipeline programs, so it is not a pure single-asset binary.
The Phase 1 dose-escalation data from August 2026 showed early signals of activity (confirmed and unconfirmed partial responses) but also dose-limiting toxicities at the highest dose. The next update in H1 2027 will include expansion cohorts and more mature efficacy/safety data. Investors should watch for the dose selected for expansion, the durability of responses, and whether the safety profile supports a competitive advantage over the approved tissue-factor ADC Tivdak (tisotumab vedotin).
Price Chart
Executive Summary
STRO-004 is Sutro Biopharma's lead wholly-owned asset, a next-generation antibody-drug conjugate targeting tissue factor (TF) for solid tumors. It entered Phase 1 (STRIVE-01) in late 2025 and early data from August 2026 showed some clinical activity (partial responses) but also dose-limiting toxicities at the highest dose. The next update with expansion cohorts is expected in the first half of 2027. Sutro has undergone major restructuring (reverse split, layoffs, management changes) and the stock trades around $9.73, far below the analyst mean price target of ~$47. The company faces competition from the approved TF-targeting ADC Tivdak (tisotumab vedotin, from Genmab/Pfizer) and has a cash runway into H1 2028. Analyst consensus is strongly bullish (18 buy/strong-buy ratings vs 2 hold/sell), but the stock has fallen sharply in 2026.
How It Works
STRO-004 is an antibody-drug conjugate (ADC) that targets tissue factor (TF), a protein found on the surface of many solid tumor cells. It is designed to deliver a potent chemotherapy drug (exatecan, a topoisomerase I inhibitor) directly to cancer cells. The antibody binds to TF on tumor cells, the ADC is absorbed, and the exatecan payload kills the cell from within. Sutro's version uses a high drug-to-antibody ratio of 8 (eight payload molecules per antibody) and its proprietary site-specific conjugation technology, aiming for better efficacy and tolerability than earlier TF-targeting ADCs.
Trial Status
The Phase 1 STRIVE-01 study is actively enrolling patients with advanced solid tumors in dose escalation. As of the Q3 2026 earnings release (November 12, 2026), the study is advancing and the next clinical update with expansion cohorts is planned for the first half of 2027. Early data from August 2026 showed confirmed and ongoing unconfirmed partial responses in heavily pretreated patients, with dose-limiting toxicities reported at the highest dose level.
The Two-Sided Case
Upcoming Catalysts
- Next clinical update and initiation of expansion cohorts for the Phase 1 STRIVE-01 study, expected in the first half of 2027
- Potential partnership or licensing interest in the TF-ADC platform
- Q4 2026 earnings report (expected early 2027)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Sutro Biopharma, Inc. PRESS-RELEASE STRO ·Originating report